volume 24, issue 3, P705-725 2010
DOI: 10.1016/j.idc.2010.05.001
View full text
|
|
Share
Keertan Dheda, Robin M. Warren, Alimuddin Zumla, Martin P. Grobusch

Abstract: Widespread global use of rifampin for 2 decades preceded the emergence of clinically significant multidrug-resistant tuberculosis (MDR-TB) in the early 1990s. The prevalence of MDR-TB has gradually increased such that it accounts for approximately 5% of the global case burden of disease (approximately half a million cases in 2007). Eclipsing this worrying trend is the widespread emergence of extensively drug-resistant TB (XDR-TB). This article reviews the insights provided by clinical and molecular epidemiolog…

expand abstract